Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.

@article{Bota2011PhaseIC,
  title={Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.},
  author={Daniela Annenelie Bota and Zeynep Eroglu and David A Reardon and Binqing Fu and Julie A. Norfleet and Annick Desjardins and Mark E. Linskey and Katherine B. Peters and Henry S. Friedman and James J. Vredenburgh},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={2056}
}
2056 Background: The only approved 2nd-line treatment for glioblastoma is Bevacizumab (Avastin), with estimated 6-month progression-free survival (PFS) rate of 42.6% and overall survival (OS) of 9.2 months. Laboratory data show Bortezomib (Velcade) is an effective agent in glioma models. We evaluated the combination of Avastin and Velcade in patients with recurrent GBM in a phase II, 2 center, open-label trial. METHODS Eligible patients were over 18 years of age, with WHO grade 4 glioma… CONTINUE READING
2 Citations
0 References
Similar Papers

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…